Pharma, power, mid-sized banks: Mayuresh Joshi's sector picks

Mayuresh Joshi is allocating capital to pharma, power, and mid-sized banks, according to an ETMarkets report. The fund manager's current positioning favors three sectors that offer distinct drivers in the current market environment.

Pharma stocks have been supported by a strong US FDA approval pipeline and steady domestic demand. Power stocks are benefiting from rising electricity consumption and continued government spending on infrastructure. Mid-sized banks are seeing credit growth and margin expansion, partly from lower funding costs.

Joshi's picks cross sectors that do not move in lockstep. That structure reduces single-sector risk while capturing multiple tailwinds around healthcare demand, industrial electricity use, and banking sector formalization.

Not all large names in these sectors fit the same profile. HDFC Bank, for instance, is a large private lender with a different risk-return setup than the mid-sized banks Joshi is targeting. AlphaScala's stock page for HDB scores the stock at 43 out of 100, labeled Mixed, with the full rating breakdown available for subscribers.

Investors tracking the same theme can compare exposure across related stocks. Infosys and Wipro, both in the technology sector, offer a different angle but share the mid-cap growth narrative that Joshi appears to favor.

The broader stock market analysis on AlphaScala covers sector-level trends and individual stock setups.

Joshi's sector tilt offers a clear anchor for watchlist decisions: pharma for regulatory catalysts, power for structural demand, and mid-sized banks for credit-cycle leverage. The mix reflects a bet that these themes can deliver without relying on broad market beta.